The SAPIEN M3 system received CE Mark in April 2025, making it the world’s first approved transfemoral transcatheter mitral ...
LONDON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented ...
Edwards Lifesciences has claimed an FDA approval for its Sapien M3 transcatheter mitral valve replacement system—marking the agency’s first in this type of implant that takes a potentiall | The ...
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...
Edwards Lifesciences Corporation EW recently launched the SAPIEN 3 Ultra RESILIA valve post the FDA approval of the same. The SAPIEN 3 Ultra RESILIA valve comprises the breakthrough RESILIA tissue ...
Medical Device Network on MSN
Edwards receives FDA approval for mitral valve replacement system
Edwards Lifesciences has received the US Food and Drug Administration (FDA) approval for its SAPIEN M3 mitral valve ...
Edwards Sapien XT: company hopes to sell in China by 2013 Edwards Lifesciences Corp. of Irvine now has a date with regulators for its highly touted Edwards Sapien heart valve. The medical device maker ...
Sapien valve: about $110 million in 2009 sales in Europe Edwards Lifesciences Corp.’s Wall Street run is expected to continue into 2010. The Irvine maker of heart valves and related devices has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback